Compare PPT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPT | ABEO |
|---|---|---|
| Founded | 1988 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.2M | 281.0M |
| IPO Year | N/A | 1980 |
| Metric | PPT | ABEO |
|---|---|---|
| Price | $3.56 | $5.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 156.1K | ★ 2.4M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 8.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | N/A | ★ $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,590.36 |
| P/E Ratio | ★ N/A | $4.03 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.25 | $3.93 |
| 52 Week High | $3.72 | $7.54 |
| Indicator | PPT | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 58.23 |
| Support Level | $3.54 | $4.53 |
| Resistance Level | $3.65 | $5.35 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 18.18 | 86.97 |
Putnam Premier Income Trust is a closed-end fixed income fund that prominently invests in U.S. government, agency, high-yield, and international fixed income securities. The fund aims to provide high current income while preserving capital by diversifying across multiple bond markets beyond traditional benchmarks. Its portfolio includes various sectors such as investment-grade and high-yield corporate bonds, mortgage-backed securities, bank loans, and emerging market debt. Revenue for the trust is generated through interest income and capital gains from its investments in a fixed fund, which operates on the New York Stock Exchange and focuses on managing a diverse range of fixed-income assets across various countries.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.